Peer Review History

Original SubmissionJuly 6, 2023
Decision Letter - Francis John Gilchrist, Editor

PONE-D-23-18845Evaluation of radiological capacity and usage in paediatric TB diagnosis: Protocol of a comparative study in Mozambique, South Africa and SpainPLOS ONE

Dear Dr. Munyangaju,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please insert comments here and delete this placeholder text when finished. 

Please take your time to read and respond to the reviewers comments. In particular it is important to discuss potential limitations of this project.

==============================

Please submit your revised manuscript by Feb 17 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Francis John Gilchrist

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Thank you for stating in your Funding Statement:

“We acknowledge support from the grant CEX2018-000806-S funded by MCIN/AEI/ 10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. Isabelle Munyangaju the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/DI21/11860045. Role of the funding sources: None of the funding sources had a role in the study’s design, conduct and reporting.”

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

3. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Additional Editor Comments (if provided):

Please take your time to read and respond to the reviewers comments. In particular it is important to discuss potential limitations of this project.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The proposed study is interesting and ambitious; it will likely require a significant amount of effort to complete, collate and then to extract accurate findings. Obviously estimates of access to care will be major challenges in Mozambique and South Africa.

A few key comments:

1. First author has superscript (17) but no corresponding institution (17) is listed.

2. The "individual" level is better described as the "institutional" level. "Multi-country" is probably better described as "multi-national".

3. The use of "clinical and radiological human resources" is vague; e.g. compare line 176 with line 204. It seems that clinical medical physicists working in radiology are excluded entirely from this study and this may impact on the integrity of the data collection and analysis to estimate "cumulative radiation dose exposure".

4. Specific Objective No. 1: surely this is "...in Mozambique, South Africa and Spain by mapping the number and distribution of CXR units...."?

5. Clarification is required on Specific Objective No. 3. The inclusion (or not) of South African data does not consistent/clear in the manuscript, and is best described in lines 223 - 230. South Africa should be mentioned in Table 1 under this objective.

6. The study also does not seem to handle dosimetry across the sites in a consistent way, which means that data analysis could be become very complex, i.e. use of NCI software is only possible for 2 institutions. It may be better to rather use dose indicators or surrogates like image size, mAs and kVp for CXR, and mAS, scan length, scan thickness and pitch for CT, for example. Sub-analysis by age (number of exams and repeat imaging of individuals with more than one contact/episode) will be necessary if all patients under the age of 16y are to be included.

7. Line 178: please define, clarify or remove the phrase "radiological diagnostics".

8. The term "radiation protection (awareness)" is very broad, as this could imply that elements like radiation shielding, e.g. line 178. Consider using another term like optimization.

9. For patient records extracted over a number of years (Mozambique and Spain) one assumes that repeat episodes in the patient once they are over the age of 16y, are excluded from the study and will not count towards cumulative dose?

Reviewer #2: This protocol paper outlines a study that will address the capacity for radiological diagnosis of paediatric TB in low-and middle-income countries with a high TB burden. The methods appear rigorous. The strengths and anticipated limitations need to be stated more clearly.

Comments

1. Please make reference to the "mixed methods" design in the title for further clarification.

2. Please provide more up-to-date references 2023 in the background section i.e., Global TB report 2023 https://www.who.int/publications/i/item/9789240083851

3. Please clearly state the study outcomes for each objective in a table similar to Table 1 (or even in the same table).

4. Since adolescents are involved in the study, I think assent forms from those older than 12 or 13, depending on national regulations, are also necessary; however, the protocol makes no mention of this. Could you please elaborate?

5. Please include the current study status in the methods section.

6. Line 172: Could you please specify how many site operation managers are intended to receive the survey?

7. Please include a risk/benefit analysis in the protocol.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

16th January 2023

Dear Editor,

We greatly appreciate the reviewers for their time and valuable comments, that have helped us improve the manuscript. Please find enclosed our point by point responses to them. The manuscript is attached in track changes to show the modifications and in a clean version.

Editor’s comments:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

• The manuscript was modified as per the requirements of the journal

2. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

• IM, ELV and ITC acknowledge the support from the grant CEX2018-000806-S funded by MCIN/AEI/ 10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. IM acknowledges the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/DI21/11860045. Role of the funding sources: None of the funding sources had a role in the study’s design, conduct and reporting. All other authors received no specific funding for this work. There was no additional external funding received for this study.

3. Data availability

• We adhere to the open data policy.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

• We have deleted the ethics statement from the declaration section, it now only appears in methods.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly.

• We do not have supporting information associated with the manuscript.

Reviewer 1 comments:

1. First author has superscript (17) but no corresponding institution (17) is listed.

• This has been double checked, there are only 16 superscripts with corresponding institutions.

2. The "individual" level is better described as the "institutional" level. "Multi-country" is probably better described as "multi-national".

• Thank you. This has been corrected to “patient level” (to avoid confusion with hospital level) and “multi-national”.

3. The use of "clinical and radiological human resources" is vague; e.g. compare line 176 with line 204. It seems that clinical medical physicists working in radiology are excluded entirely from this study and this may impact on the integrity of the data collection and analysis to estimate "cumulative radiation dose exposure".

• To maintain comparability across the 3 countries, the study does not include medical physicists in the surveys. The sites selected in Mozambique have no medical physicists, and there are few medical physicists in the country. However, where possible, we had the support of medical physicists for the collection of radiological parameters and radiological protocols.

• This has been added in line 213-217 in the manuscript

4. Specific Objective No. 1: surely this is "...in Mozambique, South Africa and Spain by mapping the number and distribution of CXR units...."?

• Corrected as suggested

5. Clarification is required on Specific Objective No. 3. The inclusion (or not) of South African data does not consistent/clear in the manuscript, and is best described in lines 223 - 230. South Africa should be mentioned in Table 1 under this objective.

• Following recent discussion with partners in South Africa, we had the possibility to revise our strategy since we submitted the manuscript for review. An amendment has been submitted to the ethics review board in South Africa so we can align with local regulations and use the most accurate methodology (providing data which will be more comparable with those obtained in the other 2 countries). Radiological parameters for each TB case treated in year 2022 will be extracted, for each clinical record, by the site PACS manager. The associated clinical data will be extracted by site clinicians and each patient record will have a unique study number which will be provided to the study team. As a result, the study team will not be able to access patient identifiers, as required by the Protection of Personal Information Act.

• Corrected in line 232 – 239 as follows: In South Africa, this methodology will be adapted to align with local regulations and use the most accurate methodology (providing data which will be more comparable with those obtained in the other 2 countries). Radiological parameters for each TB case treated in year 2022 will be extracted, for each clinical record, by the site PACS manager. The associated clinical data will be extracted by site clinicians and each patient record will have a unique study number which will be provided to the study team. As a result, the study team will not be able to access patient identifiers, as required by the Protection of Personal Information Act.

6. The study also does not seem to handle dosimetry across the sites in a consistent way, which means that data analysis could be become very complex, i.e. use of NCI software is only possible for 2 institutions. It may be better to rather use dose indicators or surrogates like image size, mAs and kVp for CXR, and mAS, scan length, scan thickness and pitch for CT, for example. Sub-analysis by age (number of exams and repeat imaging of individuals with more than one contact/episode) will be necessary if all patients under the age of 16y are to be included.

• In all study sites, we will be able to collect the radiological parameters needed to use the NCI software. In South Africa and Spain, all parameters will be extracted from DICOM headers in PACS since this is available in all selected sites. The parameters will be extracted from DICOM images and available radiological protocols at the site in Mozambique.

In light of the reviewer's suggestion, we will carry out a sub-analysis based on age as well as analyse dose indicators in addition to organ doses.

7. Line 178: please define, clarify or remove the phrase "radiological diagnostics".

• This has been removed as suggested.

8. The term "radiation protection (awareness)" is very broad, as this could imply that elements like radiation shielding, e.g. line 178. Consider using another term like optimization.

• Thank you, we have replaced it with “radiation protection optimization”.

9. For patient records extracted over a number of years (Mozambique and Spain) one assumes that repeat episodes in the patient once they are over the age of 16y, are excluded from the study and will not count towards cumulative dose?

• This is correct. This study examines paediatric exposure, which excludes all exposures beyond 16 years of age.

Reviewer 2 comments:

1. Please make reference to the "mixed methods" design in the title for further clarification.

• Change made in the title as suggested: “Evaluation of radiological capacity and usage in paediatric TB diagnosis: a mixed-method protocol of a comparative study in Mozambique, South Africa and Spain”.

2. Please provide more up-to-date references 2023 in the background section i.e., Global TB report 2023 https://www.who.int/publications/i/item/9789240083851

• Thank you, the updates have been made.

3. Please clearly state the study outcomes for each objective in a table similar to Table 1 (or even in the same table).

• Thank you, we have added the study outcomes in Table 1 in line 137

4. Since adolescents are involved in the study, I think assent forms from those older than 12 or 13, depending on national regulations, are also necessary; however, the protocol makes no mention of this. Could you please elaborate?

• This has been included in line 229 -230 and 335

• Assent forms were included for Mozambique and Spain where a sample of legal guardians will be contacted to inquire about the number of CXR and/or CT scan the child had during a TB episode.

• For all other surveys – only consent forms were included as the target population are adult healthcare professionals.

5. Please include the current study status in the methods section.

• This has been included in line 145: Currently, the study is in the data collection stage

6. Line 172: Could you please specify how many site operation managers are intended to receive the survey?

• This has been clarified. It is one operational site manager per site.

7. Please include a risk/benefit analysis in the protocol.

• Thank you very much for your comment and suggestion, we have added the following paragraph in the discussion line 386 – 399 (with additional references):

• Radiological procedures play a critical role in TB disease diagnosis and management in children, and their benefit is well documented and unquestionable. Whereas X-ray exposure from a single procedure is typically low, repeated examinations can lead to cumulative doses which might be of the order of a few tens of mGy to specific organs. As shown in the recent CT scan studies notably the large International Paediatric CT Scan Study (EPI-CT), there is a clear association between risk of brain cancers and haematological malignancies and doses typically received in CT scanning. It is therefore important to re-emphasize that the exposure of paediatric patients should be kept as low as reasonably achievable by appropriate justification of procedures and optimization of parameters. Our study aims to capture differences in exposure levels due to different health care practices (for example, the use of CT scans in Spain for the diagnosis of childhood TB, variations in radiological protocols), allowing for a more comprehensive understanding of the radiological framework in paediatric TB diagnosis internationally.

We hope that we have addressed their points satisfactorily and appreciate the opportunity to submit the new manuscript. All authors have seen and approved the revised version. We look forward to hearing from you soon.

Sincerely,

Isabelle Thierry-Chef

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Francis John Gilchrist, Editor

Evaluation of radiological capacity and usage in paediatric TB diagnosis: a mixed-method protocol of a comparative study in Mozambique, South Africa and Spain

PONE-D-23-18845R1

Dear Dr. Munyangaju,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Fran

Francis John Gilchrist

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the track changes version, line 172 has a repeat in the word "protection".

Thank you for the due consideration and implementation of the suggested changes.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Formally Accepted
Acceptance Letter - Francis John Gilchrist, Editor

PONE-D-23-18845R1

PLOS ONE

Dear Dr. Munyangaju,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Francis John Gilchrist

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .